Jeevan Scientific Technology Posts Q1 FY27 Profit Turnaround, Revenue Surges

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
Jeevan Scientific Technology Posts Q1 FY27 Profit Turnaround, Revenue Surges

Jeevan Scientific Technology reported a significant turnaround in its Q1 FY27 results, posting a profit after tax compared to a loss last year. Revenue also saw a substantial jump.

Jeevan Scientific Technology Q1 FY27 Results

Jeevan Scientific Technology Ltd announced its Q1 FY27 financial results, showcasing a strong turnaround in profitability and a significant increase in revenue.

What just happened

Jeevan Scientific Technology reported a standalone net profit after tax of Rs 1.89 crore for the quarter ended June 30, 2026. This marks a turnaround from a net loss of Rs 2.16 crore in the same quarter last year (Q1 FY26). Standalone revenue from operations surged to Rs 16.93 crore, more than double the Rs 8.21 crore reported in Q1 FY26.

Consolidated revenue from operations also saw a significant jump to Rs 18.28 crore in Q1 FY27, compared to Rs 10.06 crore in Q1 FY26. The consolidated net profit attributable to owners stood at Rs 0.54 crore, a considerable improvement from a loss of Rs 1.30 crore in the prior year period.

Reader Takeaway: Strong profit turnaround and revenue growth driven by improved operations, balanced by board re-appointments needing shareholder nod.

Why this matters

This performance indicates a robust recovery for Jeevan Scientific Technology. The turnaround in profitability and substantial revenue growth suggest improved operational efficiency and market demand. For shareholders, this is a positive sign of the company's ability to generate profits.

The backstory

In the previous year's Q1 FY26, Jeevan Scientific Technology reported a standalone net loss of Rs 2.16 crore on revenue of Rs 8.21 crore. The current quarter's results demonstrate a significant shift towards profitability.

What changes now

Investors will be looking for sustained profitability in subsequent quarters. The re-appointments of key directors, subject to shareholder approval at the upcoming AGM, will ensure leadership continuity.

Risks to watch

Continued execution on growth strategies and managing costs will be crucial. The company's reliance on its subsidiary, Nayas Laboratories Private Limited, for consolidated results means its performance is also a factor.

Peer comparison

(No specific peer comparison data available in the filing).

Context metrics (time-bound)

Standalone Revenue from Operations: Q1 FY27 Rs 16.93 crore vs Q1 FY26 Rs 8.21 crore.
Standalone Profit After Tax: Q1 FY27 Rs 1.89 crore vs Q1 FY26 (Rs 2.16) crore.

What to track next

Investors should closely watch the upcoming Annual General Meeting (AGM) on September 25, 2026, for shareholder approval of board re-appointments. Future quarterly results will indicate if this performance is sustainable.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.